A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects-Reference-Cited by-同舟云学术

A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects

Published:2022-08-03 Issue:7-8 Volume:18 Page:519-527
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Liu Zhengzhi¹,Gao Zhenyue²,Yang Wei¹,Zhang Lixiu¹,Xiao Nan²,Qu Dongmei³,Su Zhengjie¹,Xu Kaibo¹,Liu Guangwen¹,Wang Yanli¹,Ren Qing¹,Yu Shuang¹,Cheng Yang¹,Zhou Yannan¹,Deng Qiaohuan¹,Zhao Yicheng⁴⁵,Wang Zeyu¹⁶,Yang Haimiao¹

Affiliation:

1. Phase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China

2. Department of clinical research center, Chia Tai Tianqing Pharmaceutical Group Co.,Ltd, Nanjing, China

3. The Cinical Tial Quality Control Center, Ansiterui Medical Technology Consulting Co.,Ltd, Changchun, China

4. Center for Pathogen Biology and Infectious Diseases, Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, The First Hospital of Jilin University, Changchun, China

5. Clinical Medical College, Changchun University of Chinese Medicine, Changchun, China

6. Scientific Research Department, Changchun University of Chinese Medicine, Changchun, China

Funder

Chia Tai Tianqing Pharmaceutical Group Co., Ltd

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2022.2113382

Reference41 articles.

1. m6A-induced lncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1